See the DrugPatentWatch profile for keytruda

The Breakthrough of Keytruda: A Journey from Discovery to FDA Approval

The year 2014 marked a significant milestone in the history of cancer treatment with the FDA approval of Keytruda (pembrolizumab), a groundbreaking immunotherapy drug developed by Merck & Co. In this article, we will delve into the story of Keytruda's discovery, clinical trials, and eventual FDA approval, highlighting the key events and milestones that led to its success.

The Discovery of Keytruda

Keytruda is a programmed death receptor-1 (PD-1) inhibitor, a type of immunotherapy that works by blocking the PD-1 protein on immune cells, allowing them to recognize and attack cancer cells more effectively. The concept of PD-1 inhibitors dates back to the early 2000s, but it wasn't until the mid-2000s that researchers at the University of California, Los Angeles (UCLA) began exploring the potential of PD-1 inhibitors as cancer treatments.

Clinical Trials and Early Results

In 2009, Merck & Co. acquired the rights to develop the PD-1 inhibitor pembrolizumab, which was initially tested in a Phase I clinical trial in patients with advanced melanoma. The trial, known as KEYNOTE-001, was designed to evaluate the safety and efficacy of pembrolizumab in patients with unresectable or metastatic melanoma.

The results of the trial were nothing short of remarkable. In a subset of patients with advanced melanoma, pembrolizumab demonstrated an overall response rate (ORR) of 28%, with 10% of patients achieving a complete response. These early results suggested that pembrolizumab had the potential to be a game-changer in the treatment of melanoma.

FDA Approval and Beyond

On September 4, 2014, the FDA approved Keytruda for the treatment of patients with unresectable or metastatic melanoma who have progressed after prior treatment with ipilimumab and BRAF-targeted therapy, if applicable. This approval marked the first FDA approval of a PD-1 inhibitor and paved the way for the development of immunotherapy treatments for a wide range of cancers.

Since its initial approval, Keytruda has been approved for the treatment of several other types of cancer, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma.

Industry Expert Insights

"We've seen a significant shift in the way we approach cancer treatment with the approval of Keytruda," says Dr. Antoni Ribas, Professor of Medicine and Director of the Tumor Immunology Program at the University of California, Los Angeles (UCLA). "Immunotherapy has opened up new avenues for treatment, and Keytruda has been at the forefront of this revolution."

Key Takeaways

* Keytruda (pembrolizumab) was approved by the FDA in 2014 for the treatment of patients with unresectable or metastatic melanoma.
* The drug works by blocking the PD-1 protein on immune cells, allowing them to recognize and attack cancer cells more effectively.
* Keytruda has been approved for the treatment of several types of cancer, including NSCLC, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma.

Frequently Asked Questions

1. What is Keytruda used to treat?
Keytruda is used to treat patients with unresectable or metastatic melanoma, NSCLC, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma.
2. How does Keytruda work?
Keytruda works by blocking the PD-1 protein on immune cells, allowing them to recognize and attack cancer cells more effectively.
3. What are the common side effects of Keytruda?
Common side effects of Keytruda include fatigue, diarrhea, and skin rash.
4. Is Keytruda a cure for cancer?
Keytruda is not a cure for cancer, but it has been shown to be effective in slowing the growth of cancer and improving patient outcomes.
5. Can Keytruda be used in combination with other treatments?
Yes, Keytruda can be used in combination with other treatments, such as chemotherapy and radiation therapy, to enhance its effectiveness.

Sources

1. Merck & Co. (2014). FDA Approves Keytruda (pembrolizumab) for Patients with Unresectable or Metastatic Melanoma.
2. DrugPatentWatch.com. (n.d.). Pembrolizumab (Keytruda) Patent Expiration.
3. Ribas, A. (2015). Immunotherapy for Cancer: A Review of the Current Landscape. Journal of Clinical Oncology, 33(15), 1749-1756.
4. National Cancer Institute. (n.d.). Pembrolizumab (Keytruda).
5. FDA. (2014). Pembrolizumab (Keytruda) Approval Letter.